NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Stocks are struggling at the start of trade as lingering trade worries stick to this market, though investors managed to shake that off on Monday. That setup could work again for Tuesday. The S&P 500 ...

One clinical trial is assessing whether semaglutide, used in weight loss drugs, could slow the progression of dementia ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The MUSC Weight Management Center (WMC) is casting a lifeline to plus-sized individuals at wit's end with their apple cider ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.